Nanomedicine as an emerging platform for metastatic lung cancer therapy

Dalit Landesman‐Milo(Tel Aviv University), Srinivas Ramishetti(Tel Aviv University), Dan Peer(Tel Aviv University)

Cancer and Metastasis Reviews

May 6, 2015

10.1007/s10555-015-9554-4

Cited by 72

Abstract

Related Papers

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Sayda M. Elbashir, Jens Harborth, Winfried Lendeckel et al.|Nature|2001|9.4k

Doxil® — The first FDA-approved nano-drug: Lessons learned

Yechezkel Barenholz|Journal of Controlled Release|2012|4.5k

Clinical Cancer Research

Horder, William Harnett|BMJ|1941|1.3k

Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer?drug conjugate

Stewart D. Chipman, F. B. Oldham, Gabriella Pezzoni et al.|International Journal of Nanomedicine|2006|124

Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs

Ela Markovsky, Hemda Baabur‐Cohen, Ronit Satchi‐Fainaro|Journal of Controlled Release|2014|108